Werewolf Therapeutics, Inc. (HOWL): Price and Financial Metrics


Werewolf Therapeutics, Inc. (HOWL): $3.95

0.03 (+0.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add HOWL to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

HOWL Stock Price Chart Interactive Chart >

Price chart for HOWL

HOWL Price/Volume Stats

Current price $3.95 52-week high $21.67
Prev. close $3.92 52-week low $3.51
Day low $3.73 Volume 39,700
Day high $3.96 Avg. volume 234,196
50-day MA $4.57 Dividend yield N/A
200-day MA $10.86 Market Cap 109.23M

Werewolf Therapeutics, Inc. (HOWL) Company Bio


Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


HOWL Latest News Stream


Event/Time News Detail
Loading, please wait...

HOWL Latest Social Stream


Loading social stream, please wait...

View Full HOWL Social Stream

Latest HOWL News From Around the Web

Below are the latest news stories about Werewolf Therapeutics Inc that investors may wish to consider to help them evaluate HOWL as an investment opportunity.

Werewolf Therapeutics to Present at the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the SVB Leerink Global Healthcare Conference taking place virtually from February 14-18, 2022. Daniel J. Hicklin, Ph.D., President and Chief

Yahoo | February 8, 2022

Werewolf Therapeutics (NASDAQ:HOWL) Is In A Good Position To Deliver On Growth Plans

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

Yahoo | January 26, 2022

Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that management will present at the H.C. Wainwright Bioconnect Conference, taking place virtually from January 10-13, 2022. Daniel J. Hicklin, Ph.D., President and Chief Exe

Yahoo | January 5, 2022

Reid Leonard Sells 3,000 Shares of Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Stock

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) COO Reid Leonard sold 3,000 shares of the businesss stock in a transaction that occurred on Wednesday, December 15th. The shares were sold at an average price of $13.41, for a total value of $40,230.00. The transaction was disclosed in a legal filing with the SEC, which is available through this []

Dakota Financial News | December 19, 2021

Werewolf Therapeutics Added to the Nasdaq Biotechnology Index

CAMBRIDGE, Mass., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.

Intrado Digital Media | December 14, 2021

Read More 'HOWL' Stories Here

HOWL Price Returns

1-mo -11.24%
3-mo -44.83%
6-mo -72.74%
1-year -73.45%
3-year N/A
5-year N/A
YTD -66.83%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5695 seconds.